Q&A: Page 3

Exclusive interviews with industry leaders


  • Michael Severino, CEO, Tessera Therapeutics
    Image attribution tooltip
    Permission granted by Tessera
    Image attribution tooltip

    Why AbbVie’s former president has high hopes for this Flagship-backed biotech

    The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

    Karissa Waddick • Aug. 7, 2023
  • Liver model
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How CymaBay overcame a NASH failure for another shot at liver disease success

    The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

    Michael Gibney • Aug. 2, 2023
  • Oral contraceptive pill on pharmacy counter with colorful pills strips background.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    With OTC birth control approved, access battles have just begun

    Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

    Karissa Waddick • July 26, 2023
  • loic vinent head shot
    Image attribution tooltip
    Permission granted by Affini-T Therapeutics
    Image attribution tooltip

    In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

    Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

    Alexandra Pecci • July 25, 2023
  • Peter Benton
    Image attribution tooltip
    Permission granted by Worldwide Clinical Trials
    Image attribution tooltip

    A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

    Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

    Taren Grom and Meagan Parrish • July 20, 2023
  • Genetic search
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Google for genes? This AI company aims to curate the entire human genome.

    Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge. 

    Michael Gibney • July 20, 2023
  • Pharma vials
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As biologics boom, here’s how manufacturers are keeping up

    Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

    Michael Gibney • July 19, 2023
  • bullseye
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

    After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

    Alexandra Pecci • July 11, 2023
  • Merck's former global headquarters in Kenilworth, New Jersey
    Image attribution tooltip
    Permission granted by Onyx Equities
    Image attribution tooltip

    Merck’s New Jersey campus is getting a biotech makeover

    With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.

    Michael Gibney • July 11, 2023
  • Stethoscope , passport document, airplane and globe on a table.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A BMS exec’s journey around the world in 90 days

    As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.

    Karissa Waddick • July 5, 2023
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    How Sanofi is taking a ‘creative’ approach to dealmaking

    Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.

    Taren Grom • June 23, 2023
  • microscope
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    DIA’s chief exec is on a mission to grow its footprint across healthcare

    Marwan Fathallah came onboard earlier this year to lead the organization into an era of change.

    Michael Gibney • June 22, 2023
  • lightbulb pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Ranking reveals biopharma’s most innovative companies

    IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.

    Taren Grom • June 7, 2023
  • Teresa Bitetti, president, global oncology business unit, Takeda
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    How Takeda finds the hottest new science to fuel its oncology work

    Takeda's president of the global oncology business unit is always "scanning the horizon" for the partnerships that will drive the next big innovations.

    Michael Gibney • June 1, 2023
  • young cow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    From farm to pharma: How cows could play a role in the next flu breakthrough

    SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.

    Alexandra Pecci • May 16, 2023
  • Christopher Boone AbbVie
    Image attribution tooltip
    Permission granted by Christopher Boone AbbVie
    Image attribution tooltip

    AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’

    With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.

    Taren Grom • May 10, 2023
  • Bahija Jallal Immunocore 2
    Image attribution tooltip
    Permission granted by Bahija Jallal
    Image attribution tooltip

    How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

    The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

    Taren Grom • May 5, 2023
  • Martine van Vugt, executive vice president and chief strategy officer, Genmab
    Image attribution tooltip
    Permission granted by Genmab
    Image attribution tooltip

    From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

    Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.

    Michael Gibney • May 2, 2023
  • Kurt Harrington bicycle
    Image attribution tooltip
    Permission granted by Kurt Harrington
    Image attribution tooltip

    A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient

    The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.

    Taren Grom • May 1, 2023
  • 5 minutes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 minutes with — DTRA’s Dr. Amir Kalali

    An industry veteran, innovator and curator, Dr. Amir Kalali discusses the high points of his career and his go-to productivity hack.

    Taren Grom • April 28, 2023
  • Lou Tartaglia, founder and managing partner, Cure Ventures
    Image attribution tooltip
    Permission granted by Cure Ventures
    Image attribution tooltip

    Cure Ventures has $350M to pour deep into biotech ‘company building’

    The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.

    Michael Gibney • April 20, 2023
  • Chris Benecchi, chief business officer, Sage Therapeutics
    Image attribution tooltip
    Permission granted by Sage
    Image attribution tooltip

    Depression has long been treated chronically — Sage wants to change that

    Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

    Michael Gibney • April 18, 2023
  • Awan Ahsan
    Image attribution tooltip
    Permission granted by Ahsan Awan
    Image attribution tooltip

    5 minutes with — Genlantis Diagnostics’ Ahsan Awan

    A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”

    Taren Grom • April 14, 2023
  • Peyton Howell Parexel
    Image attribution tooltip
    Permission granted by Peyton Howell
    Image attribution tooltip

    5 minutes with — Parexel’s Peyton Howell

    The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."

    Taren Grom • April 7, 2023
  • cardio
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Amgen’s aim for a ‘moonshot’ in cardiovascular disease

    A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.  

    Taren Grom • April 5, 2023